Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Intra-Cellular Therapies Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ITCI
Nasdaq
2836
https://www.intracellulartherapies.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Intra-Cellular Therapies Inc
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467%
- Mar 24th, 2024 2:31 pm
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
- Mar 19th, 2024 12:30 pm
Intra-Cellular Therapies Inc Chairman, President & CEO Sharon Mates Sells 61,277 Shares
- Mar 12th, 2024 5:16 am
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
- Mar 6th, 2024 1:00 pm
EVP and General Counsel Michael Halstead Sells Shares of Intra-Cellular Therapies Inc
- Feb 28th, 2024 10:01 am
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
- Feb 27th, 2024 1:00 pm
Intra-Cellular Therapies Full Year 2023 Earnings: EPS Beats Expectations
- Feb 24th, 2024 2:37 pm
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:59 pm
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
- Feb 23rd, 2024 1:41 pm
Intra-Cellular Therapies Inc (ITCI) Reports Robust Revenue Growth in 2023 Earnings
- Feb 22nd, 2024 12:53 pm
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
- Feb 22nd, 2024 12:30 pm
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Feb 19th, 2024 3:00 pm
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
- Feb 15th, 2024 10:10 pm
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Feb 15th, 2024 3:00 pm
Biotech Leader Intra-Cellular Therapies Nears Buy Point Ahead Of Earnings Report
- Feb 13th, 2024 4:51 pm
Dow Jones Futures: Market Risks Rising With 5 Stocks In Buy Zones
- Feb 12th, 2024 1:14 pm
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Path To Profitability
- Feb 12th, 2024 1:06 pm
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
- Feb 8th, 2024 1:00 pm
Intra-Cellular Therapies Inc EVP, Chief Medical Officer Suresh Durgam Sells 6,167 Shares
- Feb 6th, 2024 4:11 am
Intra-Cellular Therapies Inc CEO Sharon Mates Sells 191,362 Shares
- Jan 19th, 2024 2:01 am
Scroll